Free Trial

Bicara Therapeutics (BCAX) Stock Price, News & Analysis

Bicara Therapeutics logo
$12.06 +0.06 (+0.50%)
Closing price 04:00 PM Eastern
Extended Trading
$12.08 +0.01 (+0.12%)
As of 07:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Bicara Therapeutics Stock (NASDAQ:BCAX)

Key Stats

Today's Range
$11.57
$12.13
50-Day Range
$8.71
$12.06
52-Week Range
$7.80
$28.09
Volume
199,254 shs
Average Volume
275,067 shs
Market Capitalization
$657.99 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$32.25
Consensus Rating
Buy

Company Overview

Bicara Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
48th Percentile Overall Score

BCAX MarketRank™: 

Bicara Therapeutics scored higher than 48% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Bicara Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Bicara Therapeutics has only been the subject of 3 research reports in the past 90 days.

  • Read more about Bicara Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Bicara Therapeutics are expected to grow in the coming year, from ($2.59) to ($1.74) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Bicara Therapeutics is -3.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Bicara Therapeutics is -3.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Bicara Therapeutics has a P/B Ratio of 1.33. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Bicara Therapeutics' valuation and earnings.
  • Short Interest

    There is no current short interest data available for BCAX.
  • Dividend Yield

    Bicara Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Bicara Therapeutics does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for BCAX.
  • News Sentiment

    Bicara Therapeutics has a news sentiment score of 1.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Bicara Therapeutics this week, compared to 4 articles on an average week.
  • Search Interest

    1 people have searched for BCAX on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Bicara Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    15.50% of the stock of Bicara Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Read more about Bicara Therapeutics' insider trading history.
Receive BCAX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bicara Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BCAX Stock News Headlines

2013 Bitcoin miner reveals his trading system (free)
While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematically extracting profits from the $4 billion that changes hands in crypto every single day.tc pixel
See More Headlines

BCAX Stock Analysis - Frequently Asked Questions

Bicara Therapeutics' stock was trading at $17.42 at the start of the year. Since then, BCAX shares have decreased by 30.8% and is now trading at $12.06.

Bicara Therapeutics Inc. (NASDAQ:BCAX) posted its quarterly earnings data on Tuesday, August, 12th. The company reported ($0.50) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.04.

Bicara Therapeutics (BCAX) raised $315 million in an IPO on Friday, September 13th 2024. The company issued 17,500,000 shares at a price of $18.00 per share.

Bicara Therapeutics' top institutional shareholders include Vestal Point Capital LP (9.16%), Geode Capital Management LLC (1.23%), Bank of America Corp DE (0.83%) and Schroder Investment Management Group (0.78%).
View institutional ownership trends
.

Shares of BCAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
8/12/2025
Today
9/04/2025
Next Earnings (Estimated)
11/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:BCAX
Previous Symbol
NASDAQ:BCAX
CIK
2023658
Fax
N/A
Employees
32
Year Founded
N/A

Price Target and Rating

High Price Target
$48.00
Low Price Target
$8.00
Potential Upside/Downside
+168.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
10 Analysts

Profitability

EPS (Trailing Twelve Months)
($3.17)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$68 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-21.67%
Return on Assets
-20.89%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
25.80
Quick Ratio
25.80

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$7.98 per share
Price / Book
1.51

Miscellaneous

Outstanding Shares
54,563,000
Free Float
N/A
Market Cap
$656.67 million
Optionable
N/A
Beta
N/A

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:BCAX) was last updated on 9/4/2025 by MarketBeat.com Staff
From Our Partners